Abstract
Low bone mass predicts future fracture risk as well as high cholesterol or high blood pressure can predict the risk of heart disease or stroke. Prevention of the first fracture should be a clinical goal. In patients without fractures, osteopenia and osteoporosis can be diagnosed based on the extent of reduction in bone mass below mean peak bone mass of young healthy individuals. As bone mass decreases, fracture risk increases exponentially. Clinical situations in which an assessment of bone mass and fracture risk affects therapeutic decisions include estrogen deficiency, vertebral abnormalities, radiographic osteopenia, asymptomatic primary hyperparathyroidism, and long-term corticosteroid therapy. Serial measurements can also be used to monitor the effects of osteoporosis treatments. The appropriate technique and skeletal site for bone mass measurements should be chosen based on the patient's circumstances and the precision of measurement. A clinical interpretation can enhance the value of computer-generated bone mass measurement reports and improve decision making.
| Original language | English |
|---|---|
| Pages (from-to) | 361-372 |
| Number of pages | 12 |
| Journal | Seminars in Arthritis and Rheumatism |
| Volume | 25 |
| Issue number | 6 |
| DOIs | |
| State | Published - 1996 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Anesthesiology and Pain Medicine
- Orthopedics and Sports Medicine
- Rheumatology
Cite this
Clinical utility of bone mass measurements in adults : Consensus of an international panel. / Miller, P. D.; Bonnick, S. L.; Rosen, C. J.; Altman, R. D.; Avioli, L. V.; Dequeker, J.; Felsenberg, D.; Genant, H. K.; Gennari, C.; Harper, K. D.; Hodsman, A. B.; Kleerekoper, M.; Mautalen, C. A.; McClung, M. R.; Meunier, P. J.; Nelson, D. A.; Peel, N. F A; Raisz, L. G.; Recker, Robert R.
In: Seminars in Arthritis and Rheumatism, Vol. 25, No. 6, 1996, p. 361-372.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical utility of bone mass measurements in adults
T2 - Consensus of an international panel
AU - Miller, P. D.
AU - Bonnick, S. L.
AU - Rosen, C. J.
AU - Altman, R. D.
AU - Avioli, L. V.
AU - Dequeker, J.
AU - Felsenberg, D.
AU - Genant, H. K.
AU - Gennari, C.
AU - Harper, K. D.
AU - Hodsman, A. B.
AU - Kleerekoper, M.
AU - Mautalen, C. A.
AU - McClung, M. R.
AU - Meunier, P. J.
AU - Nelson, D. A.
AU - Peel, N. F A
AU - Raisz, L. G.
AU - Recker, Robert R.
PY - 1996
Y1 - 1996
N2 - Low bone mass predicts future fracture risk as well as high cholesterol or high blood pressure can predict the risk of heart disease or stroke. Prevention of the first fracture should be a clinical goal. In patients without fractures, osteopenia and osteoporosis can be diagnosed based on the extent of reduction in bone mass below mean peak bone mass of young healthy individuals. As bone mass decreases, fracture risk increases exponentially. Clinical situations in which an assessment of bone mass and fracture risk affects therapeutic decisions include estrogen deficiency, vertebral abnormalities, radiographic osteopenia, asymptomatic primary hyperparathyroidism, and long-term corticosteroid therapy. Serial measurements can also be used to monitor the effects of osteoporosis treatments. The appropriate technique and skeletal site for bone mass measurements should be chosen based on the patient's circumstances and the precision of measurement. A clinical interpretation can enhance the value of computer-generated bone mass measurement reports and improve decision making.
AB - Low bone mass predicts future fracture risk as well as high cholesterol or high blood pressure can predict the risk of heart disease or stroke. Prevention of the first fracture should be a clinical goal. In patients without fractures, osteopenia and osteoporosis can be diagnosed based on the extent of reduction in bone mass below mean peak bone mass of young healthy individuals. As bone mass decreases, fracture risk increases exponentially. Clinical situations in which an assessment of bone mass and fracture risk affects therapeutic decisions include estrogen deficiency, vertebral abnormalities, radiographic osteopenia, asymptomatic primary hyperparathyroidism, and long-term corticosteroid therapy. Serial measurements can also be used to monitor the effects of osteoporosis treatments. The appropriate technique and skeletal site for bone mass measurements should be chosen based on the patient's circumstances and the precision of measurement. A clinical interpretation can enhance the value of computer-generated bone mass measurement reports and improve decision making.
UR - http://www.scopus.com/inward/record.url?scp=0029885623&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029885623&partnerID=8YFLogxK
U2 - 10.1016/S0049-0172(96)80001-1
DO - 10.1016/S0049-0172(96)80001-1
M3 - Article
C2 - 8792508
AN - SCOPUS:0029885623
VL - 25
SP - 361
EP - 372
JO - Seminars in Arthritis and Rheumatism
JF - Seminars in Arthritis and Rheumatism
SN - 0049-0172
IS - 6
ER -